Roche Holding AG
RHO5
Company Profile
- Business description- Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales. 
- Contact- Grenzacherstrasse 124 
 Basel4070
 CHE- T: +41 616881111 - E: investor.relations@roche.com 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Drug Manufacturers - General - Fiscal Year End- 31 December 2025 - Employees- 103,249 
Roche Holding AG News & Analysis
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,205.00 | 1.70 | -0.02% | 
| CAC 40 | 8,157.29 | 43.59 | -0.53% | 
| DAX 40 | 24,118.89 | 5.32 | -0.02% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,760.06 | 3.92 | 0.04% | 
| HKSE | 26,050.08 | 232.61 | -0.89% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 52,211.69 | 886.08 | 1.73% | 
| NZX 50 Index | 13,544.51 | 85.22 | 0.63% | 
| S&P 500 | 6,822.34 | 68.25 | -0.99% | 
| S&P/ASX 200 | 8,909.10 | 4.10 | -0.05% | 
| SSE Composite Index | 3,961.62 | 25.28 | -0.63% |